The coronavirus vaccine – ChAdOx1 nCoV-19 – currently under development in the University of Oxford has triggered a strong immune response after a clinical trial, BBC reports.
“We’re really pleased with the results published today as we’re seeing both neutralizing antibodies and T-cells,” Prof Andrew Pollard, from the Oxford research group told the BBC.
“They’re extremely promising and we believe the type of response that may be associated with protection.”
The trial involved 1,077 people who were injected with the vaccine, and it has triggered an immune response against the virus.
The Oxford University trial is one of the many high-profile trials going across different parts of the world. Just recently, Russia announced it has successfully conducted the clinical trials of its coronavirus vaccine, proving the efficacy of the virus on humans.
The BBC notes, Oxford’s trail, though very promising, is still in the early stages of development. However, the UK has already ordered 100 million doses of the vaccine.
Oxford University vaccine is essentially a genetically engineered virus that causes the common cold in chimpanzees but has been heavily modified so that it cannot cause illness in humans and also make it “look” more like coronavirus.
As of now, 90% of volunteers developed an immune response for the virus, and those who were given two doses had maximized response.
However, the vaccine did trigger side effects, although none life-threatening. 70% of the people injected with the vaccine did report either fever or headache, which the researches say could be managed with paracetamol.
The next step will involve 10,000 plus volunteers.